Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroVive Pharmaceutical and to-BBB are set to jointly develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies.
Subscribe to our email newsletter
NeuroVive will fund the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.
to-BBB CSO Pieter Gaillard said that the blood-brain barrier (BBB) is indeed a significant obstacle in the treatment of CNS disorders, to-BBB’s proprietary G-Technology can safely enhance drug delivery to the brain and they are excited to address this with NeuroVive’s cyclosporin-based pharmaceuticals.
NeuroVive CEO Mikael Bronnegard said that the deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke.
to-BBB CEO Willem van Weperen said that they are convinced that synergies in research and clinical platforms as well as business and commercial strategies between to-BBB and NeuroVive will result in a strong partnership that will benefit patients with these CNS diseases.